Asset profile
JMKX000623
Small molecule
Evidence outlook · results not reported
NCT06221241 · Diabetic Peripheral Neuropathic Pain
The lead study's design has limits that temper confidence (see the rationale below), and its results have not been reported. This tier describes the design, not an outcome.
NCT06221241: This randomized, quadruple-blind, placebo- and active-comparator-controlled phase 2 trial in 220 people with diabetic peripheral neuropathic pain is designed to compare change in average daily pain score against placebo over 12 weeks. Results have not yet been posted.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
15 competitors in this universe: 2 direct rivals (same mechanism and indication), 0 same-class, 13 same-indication; 9 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| JMKX000623: this drug | Phase 2 | Small molecule | Voltage-gated sodium channel NaV1.8 | ||
| Suzetrigine | Approved | Small molecule | Voltage-gated sodium channel NaV1.8 | ||
| VX-993 | Phase 2 | Small molecule | Voltage-gated sodium channel NaV1.8 | ||
| Capsaicin (Qutenza) | Approved | Small molecule | TRPV1 (transient receptor potential vanilloid 1) channel | ||
| Duloxetine (Cymbalta) | Approved | Small molecule | Serotonin/norepinephrine transporter, Serotonin and norepinephrine transporters (SERT/NET) | ||
| Pregabalin | Approved | Small molecule | α2δ subunit of voltage-gated calcium channels | ||
| Tapentadol | Approved | Small molecule | Mu-opioid receptor and norepinephrine transporter (NET) | ||
| Crisugabalin | Phase 3 | Small molecule | α2δ-1 subunit of voltage-gated calcium channels | ||
| Mirogabalin | Phase 3 | Small molecule | α2δ-1 subunit of voltage-gated calcium channels | ||
| HL-1186 | Phase 2/3 | Small molecule | — | ||
| HRS-2129 | Phase 2/3 | Small molecule | — | ||
| LY4065967 | Phase 2 | Small molecule | Angiotensin II type 2 receptor (AT2R) (antagonist) | ||
| NRD135S.E1 | Phase 2 | Small molecule | — | ||
| Pilavapadin | Phase 2 | Small molecule | AP2-associated kinase 1 (AAK1) | ||
| Pirenzepine (topical) | Phase 2 | Small molecule | Muscarinic acetylcholine receptor (M3), Muscarinic M1 receptor (antagonist) | ||
| AJH-2947 | Phase 1 | Small molecule | — |
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.